From discovery to market: The role of IP strategy in drug development

49 minute read
08 November 2021

With vaccine brand names still very much top-of-mind for Canadians, Gowling WLG's own Brian Kingwell and Dr. Sonia Ziesche took part in a recent online panel discussion surrounding drug development and intellectual property. The event touched on everything from identifying intellectual property during R&D to the importance of freedom to operate analysis, international filing strategies and portfolio management, and the unique industry challenges brought to light due to the COVID-19 pandemic.

Click below to watch a recap of the event, co-sponsored by Gowling WLG and Life Sciences British Columbia.

Brian Kingwell, a partner, patent agent, and trademark agent in the firm's Vancouver office, has more than two decades of experience in patent prosecution and strategic patent portfolio counselling. Dr. Sonia Ziesche, a principal, patent agent, and the chair of the firm's Life Sciences Group in Vancouver, is known for developing targeted patent programs designed to capture innovations and provide a competitive advantage.

The pair from Gowling WLG were joined by Dr. Isabelle Riedl, senior supervisor, intellectual property, at Medicago. The latter is a Canadian biotechnology company focused on producing candidate vaccines and medications through the use of plants.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.